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The phenomenon of prion strains with distinct biological characteristics has been 23 
hypothesized to be involved in the structural diversity of abnormal prion protein (PrPSc). 24 
However, the molecular basis of the transmission of strain properties remains poorly 25 
understood. Real-time quaking-induced conversion (RT-QUIC) is a cell-free system that 26 
uses E. coli-derived recombinant PrP (rPrP) for the sensitive detection of PrPSc. To 27 
investigate whether properties of various prion strains can be transmitted to amyloid 28 
fibrils consisting of rPrP (rPrP-fibrils) using RT-QUIC, we examined the secondary 29 
structure, conformational stability and infectivity of rPrP-fibrils seeded with PrPSc 30 
derived from either the Chandler or 22L strain. In the first round of the reaction there 31 
were differences in the secondary structures, especially in bands attributed to β-sheets, as 32 
determined by infrared spectroscopy, and conformational stability between 33 
Chandler-seeded (1st-rPrP-fibCh) and 22L-seeded rPrP-fibrils (1st-rPrP-fib22L). Of note, 34 
specific identifying characteristics of the two rPrP-fibril-types seen in the β-sheets 35 
resembled those of the original PrPSc. Furthermore, the conformational stability of 36 
1st-rPrP-fibCh was significantly higher than that of 1st-rPrP-fib22L, as with Chandler- and 37 
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22L-PrPSc. The survival periods in mice inoculated with 1st-rPrP-fibCh or 1st-rPrP-fib22L 38 
were significantly shorter than those of the mice inoculated with mock 1st-QUIC mixtures. 39 
In contrast, these biochemical characteristics were no longer evident in subsequent 40 
rounds, suggesting that nonspecific uninfected rPrP-fibrils became predominant probably 41 
because of their rapid growth rate. Together, these findings show that at least some 42 
strain-specific conformational properties can be transmitted to rPrP-fibrils and unknown 43 
cofactors or environmental conditions may be required for further conservation. 44 
 45 
Importance 46 
The phenomenon of prion strains with distinct biological characteristics is assumed to 47 
result from the conformational variations in the abnormal prion protein (PrPSc). However, 48 
important questions remain about the mechanistic relationship between the 49 
conformational differences and the strain diversity, including how to transmit 50 
strain-specific conformations. In this study, we investigated whether properties of diverse 51 
prion strains can be transmitted to amyloid fibrils consisting of E. coli-derived 52 
recombinant PrP (rPrP) generated in the real-time quaking-induced conversion 53 
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(RT-QUIC), a recently-developed in vitro PrPSc formation method. We demonstrate that 54 
at least some of the strain-specific conformational properties can be transmitted to 55 
rPrP-fibrils in the first round of RT-QUIC by examining the secondary structure, 56 
conformational stability and infectivity of rPrP-fibrils seeded with PrPSc derived from 57 
either the Chandler or 22L prion strain. We believe that these findings will advance our 58 
understanding of the conformational basis underlying prion strain diversity.  59 
 60 
Introduction 61 
Prion diseases, or transmissible spongiform encephalopathies (TSE), are infectious and 62 
fatal neurodegenerative disorders characterized by progressive spongiform changes and 63 
the accumulation of abnormal prion protein (PrPSc) in the central nervous system. 64 
Although the pathogenic mechanisms have not been fully elucidated, prion disease is 65 
thought to occur through autocatalytic conversion of normal prion protein (PrPC) to PrPSc 66 
(1, 2), known as the protein-only hypothesis. Some biophysical properties are known to 67 
differ between PrPC and PrPSc. PrPC is monomeric, detergent-soluble and 68 
protease-sensitive, while PrPSc is polymeric, detergent-insoluble and partially 69 
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protease-resistant (3). These differences are most likely due to the different 70 
conformations of the two isoforms. PrPC is largely α-helical, whereas PrPSc is 71 
substantially enriched in β-sheets (4, 5), frequently resulting in amyloid fibril formation.  72 
The existence of diverse prion strains in mammalian species manifesting in 73 
phenotypic differences is well known. The strain-specific characteristics are usually 74 
maintained upon serial passage in the same species, and may be explained by 75 
conformational variations in the PrPSc. Indeed, strain-dependent differences in 76 
β-sheet-rich structures of PrPSc have been demonstrated by infrared spectroscopy (6-9). 77 
In addition, the conformational stability of PrPSc differed among prion strains, as 78 
demonstrated by guanidine hydrochloride (GdnHCl) denaturation assay followed by 79 
protease digestion (10, 11). However, the mechanistic relationship between PrPSc 80 
conformational differences and the molecular basis of prion strains remains poorly 81 
understood. 82 
Various in vitro PrPSc formation methods have been developed to elucidate the 83 
pathogenesis of the prion diseases. One of these methods, protein misfolding cyclic 84 
amplification (PMCA), enabled an exponential amplification of PrPSc in vitro by 85 
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sonication-induced fragmentation of large PrPSc polymers into smaller units (12). The 86 
amplified PrPSc was accompanied by an increase in infectivity using normal brain 87 
homogenate (BH) as a source of PrPC substrates (BH-PMCA) (13). Furthermore, PrPSc 88 
generated by BH-PMCA from five different mouse prion strains retained the 89 
strain-specific properties (14). In addition, prion infectivity could be propagated when 90 
purified brain-derived PrPC or baculovirus-derived PrPC was used as substrates in the 91 
presence of certain cofactors such as nucleic acids and BH from PrP-deficient mice 92 
(15-17). These results provide strong evidence to support the protein-only hypothesis, but 93 
the structural basis of prion pathogenesis, including the tertiary structure of PrPSc, has not 94 
been fully clarified. 95 
On the other hand, the use of E. coli-derived purified recombinant PrP (rPrP) 96 
offers an advantage over conformational analyses, which generally require a high purity 97 
and a large quantity of the target protein. Spontaneously-polymerized amyloid fibrils of 98 
rPrP have been reported to induce the accumulation of PrPSc in the brains of 99 
PrP-overexpressing transgenic (Tg) mice (18-20) and some wild-type hamsters (21), 100 
however the incubation periods spanned no less than several hundred days and none of 101 
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the wild-type hamsters developed any neurological signs at first passage, indicating that 102 
the level of infectivity generated in these studies is very low. More recently, wild-type 103 
mice developed clinical disease typical of TSE around 130 days after injection of 104 
proteinase K-resistant rPrP fibrils (rPrP-fibrils) generated by unseeded-PMCA in the 105 
presence of 1-palmitoyl-2-oleoylphosphatidylglycerol (POPG), a synthetic lipid 106 
molecule, and total liver RNA (22).  Although these results were reproduced by the same 107 
group (23), others have reported that rPrP-fibrils generated by the same method were 108 
unable to induce either neuropathological changes or the accumulation of PrPSc (24). 109 
Thus, the role of POPG and RNA in the de novo generation of infectious rPrP-fibrils 110 
remains controversial.  111 
Meanwhile, two different seeded-PMCA reaction studies using rPrP 112 
(rPrP-PMCA) as a substrate have demonstrated the propagation of moderate levels of 113 
prion infectivity. One study showed that hamster rPrP can be converted to rPrP-fibrils 114 
capable of inducing TSE in the presence of SDS, a synthetic anionic detergent, but there 115 
were great variations in the attack rate and the incubation period, which ranged from 119 116 
to 401 days (25). Another study revealed that phosphatidylethanolamine (PE), a 117 
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phospholipid found in biological membranes, enhances conversion of mouse rPrP into 118 
rPrP-fibrils capable of inducing TSE after around 400 days of incubation periods with a 119 
100% attack rate (26, 27). Of note, three different strains used as a seed were converted 120 
into a single strain with unique strain properties during the serial rPrP-PMCA 121 
experiments (27). These studies suggest that a certain amphipathic molecule such as PE is 122 
a required cofactor for the propagation of prion infectivity in vitro, but not for the 123 
transmission of strain-specific properties.  124 
The recently developed “real-time quaking-induced conversion” (RT-QUIC) is 125 
a sensitive prion detection method (28, 29), in which intermittent shaking enhances the 126 
conversion of soluble rPrP into amyloid fibrils in the presence of PrPSc.  The aim of the 127 
present research was to investigate whether properties of diverse prion strains can be 128 
transmitted to rPrP-fibrils generated in the RT-QUIC. We produced proteinase K-resistant 129 
rPrP-fibrils seeded with minute quantities of mouse-adapted scrapie (Chandler or 22L 130 






MATERIALS AND METHODS 135 
Recombinant mouse PrP expression and purification 136 
Recombinant PrP (rPrP) equivalent to residues 23-231 of the mouse PrP sequence was 137 
expressed, refolded into a soluble form, and purified essentially as previously described 138 
(30). The concentration of rPrP was determined by measuring the absorbance at 280 nm. 139 
The purity of the final protein preparations was ≥ 99 %, as estimated by SDS-PAGE, 140 
immunoblotting and liquid chromatography-mass spectrometry (data not shown). After 141 
purification, aliquots of the proteins were stored at -80 oC in 10 mM phosphate buffer, 142 
pH6.8 or distilled water. 143 
 144 
Preparation of brain homogenates 145 
Brain tissues were homogenized at 10% (w/v) in ice-cold PBS supplemented with a 146 
protease inhibitor mixture (Roche) using a multi-bead shocker (Yasui Kikai, Osaka, 147 
Japan). After centrifugation at 2,000 g for 2 min, supernatants were collected and frozen 148 
at -80 oC until use. Total protein concentrations were determined by the BCA protein 149 
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assay (Pierce). The PrPSc concentrations in the brain homogenates were estimated by 150 
dot-blot analysis using a reference standard of rPrP, as previously described (31). 151 
 152 
RT-QUIC experiments 153 
We prepared reaction mixtures in a 96-well, optical, black bottom plate (Nunc 265301) to 154 
a final total volume of 100 µl. To avoid contamination, we prepared non-infectious 155 
materials inside a biological safety cabinet in a prion-free laboratory and used 156 
aerosol-resistant tips. The final concentrations of reaction buffer components were 300 157 
mM NaCl, 50 mM HEPES pH 7.5, and 10 µM Thioflavin T (ThT). The concentration of 158 
rPrP was 50 or 100 µg/ml, and only freshly-thawed rPrP was used. Brain homogenate was 159 
diluted with reaction buffer prior to the reactions. The 96-well plate was covered with 160 
sealing tape (Nunc 236366) and incubated at 40 oC in a plate reader (Infinite M200 161 
fluorescence plate reader, TECAN) with intermittent shaking, consisting of 30 s of 162 
circular shaking at the highest speed and no shaking for 30 s, with a 2 min pause to 163 
measure the fluorescence. The kinetics of amyloid formation was monitored by the 164 
bottom reading of the fluorescence intensity every 10 min using 440-nm excitation and 165 
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485-nm emission wavelength of monochromators.   166 
 167 
RT-QUIC products analysis 168 
For detection of protease-resistant rPrP, 10 μl of the QUIC samples (1 µg of rPrP) was 169 
diluted with 40µl of buffer (300 mM NaCl, 50 mM HEPES pH 7.5) and digested with 10 170 
µg/ml of proteinase K (PK) at 37 oC for 1 h. After adding Pefabloc (Roche) at a final 171 
concentration of 4 mM and 20 µg of thyroglobulin, the proteins were precipitated with 4 172 
volumes of methanol. The samples were heated in sample buffer (2% SDS, 5% 173 
β-mercaptoethanol, 5% sucrose, 0.005% bromophenol blue and 62.5 mM Tris-HCl; pH 174 
6.8) at 95 oC for 5 min, and then loaded onto 10% BisTris NuPAGE gels (Invitrogen). 175 
Proteins were transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, 176 
MA, USA). The membranes were probed with polyclonal anti-PrP antibody R20 (epitope 177 
located at mouse PrP amino acids 218-231) or ICSM35 (D-Gen, London, UK). 178 
 179 
Transmission electron microscopy 180 
Negative staining was done on carbon supporting film grids, which were glow-discharged 181 
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before staining. The 10 µl samples were adsorbed to the grids for 3 min, then the residual 182 
solution was absorbed by filter paper. The grids were stained with 20 µl of fleshly filtered 183 
stain (2% uranyl acetate). Once dry, the samples were viewed in a transmission electron 184 
microscope (JEM-1200EX, JEOL, Japan).  185 
 186 
Fourier transform infrared spectroscopy (FTIR) 187 
FTIR spectra were measured with a Bruker Tensor 27 FTIR instrument (Bruker Optics) 188 
equipped with an MCT detector cooled with liquid nitrogen. 300 µl each of the QUIC 189 
samples (30 µg of rPrP) were pelleted by centrifugation for 1 h at 77,000 g, and 190 
resuspended in 20 µl buffer (300 mM NaCl, 50 mM HEPES pH 7.5). The slurry was 191 
loaded into BioATRcell II. PrPSc was purified from the brains of mice infected with the 192 
mouse-adapted Chandler and 22L prion using a combination of detergent solubilization, 193 
centrifugation at ultrahigh speeds and PK digestion (4, 32), and 15 µl of purified PrPSc 194 
were directly loaded. 128 scans at 4 cm−1 resolution were collected for each sample under 195 
constant purging with nitrogen, corrected for water vapor, and background spectra of 196 




Conformational stability assay 199 
10 µl of the QUIC products (equivalent to 1 µg of rPrP) and brain homogenates (80 µg of 200 
total proteins) were mixed with 22 µl of various concentrations of guanidine 201 
hydrochloride (GdnHCl) at a final concentration of 0 to 5 M and 0 to 3.5 M, respectively, 202 
and the mixed samples were incubated at 37 oC for 1h. After adjusting the final GdnHCl 203 
concentration of the QUIC products to 1 M and the brain homogenates to 0.6 M, the 204 
samples were digested with PK (10 µg/ml) at 37 oC for 1h, and analyzed by Western 205 
blotting following methanol precipitation. The bands were visualized using Attophos AP 206 
Fluorescent Substrate system (Promega) and quantified using Molecular Imager FX 207 
(BIO-RAD). The sigmoidal patterns of denaturation curves were plotted using a 208 
Boltzmann curve fit. The concentration of GdnHCl required to denature 50% of 209 
PK-resistant fragments ([GdnHCl]1/2) was estimated from the denaturation curves. 210 
 211 
Bioassay 212 
Male 4-week-old ddY mice were intracerebrally inoculated with 40 µl of QUIC products 213 
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(equivalent to 4 µg rPrP). As controls for rPrP-fibrils, we performed a mock QUIC 214 
procedure using seed-only solutions that contained the same concentration of PrPSc as 1st- 215 
-rPrP-fibril (1 pg/µl) or 5th-rPrP-fibril (1 × 10-8 pg/µl), then added the same amount of 216 
rPrP, and inoculated the mixtures into mice. Brain homogenates were serially diluted 217 
with PBS, from 100 to 10-7, and 20 µl of each dilution was intracerebrally inoculated. 218 
Mice were monitored weekly until the terminal stage of disease or sacrifice. Clinical 219 
onset was determined as the presence of 3 or more of the following signs: greasy and/or 220 
yellowish hair, hunchback, weight loss, yellow pubes, ataxic gait and nonparallel hind 221 
limbs. The 50% lethal dose (LD50) was determined according to the Behrens-Karber 222 
formula. Animals were cared for in accordance with the Guidelines for Animal 223 
Experimentation of Nagasaki University. 224 
 225 
Histopathology and Lesion Profiles 226 
The brain tissue was fixed in 4% paraformaldehyde, and 5 µm paraffin sections prepared 227 
on PLL coat slides using a microtome. After deparaffinization and rehydration, the tissue 228 
sections were stained with hematoxylin and eosin. The pattern of vacuolation was 229 
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examined in 8 fields per slice from the hippocampus, cerebral cortex, hypothalamus, pons 230 
and cerebellum. Spongiform degeneration was scored using the following scale: 0, no 231 
vacuoles; 1, a few vacuoles widely and unevenly distributed; 2, a few vacuoles evenly 232 
scattered; 3, moderate numbers of vacuoles evenly scattered; 4, many vacuoles with some 233 
confluences; 5, dense vacuolation. 234 
 235 
Statistical Analysis 236 
The fibril-length or width determined by electron microscopy analysis was subjected to 237 
one-way analysis of variance (ANOVA) followed by Tukey-Kramer test. The data of the 238 
conformational stability test was analyzed by one-way ANOVA followed by student’s 239 
t-test. The data analysis of the survival times was evaluated by Logrank test.  The data of 240 





Conversion of the soluble form of mouse recombinant PrP into amyloid fibrils by 244 
RT-QUIC  245 
We first tested whether formation of mouse rPrP amyloid fibrils could be 246 
induced in the RT-QUIC by monitoring levels of ThT fluorescence. We observed positive 247 
ThT fluorescence in the presence of diluted Chandler-brain homogenate (BH) or 22L-BH 248 
containing 100 pg of PrPSc (Fig. 1A), whereas negative control reactions seeded with 249 
comparable dilutions of normal brain homogenate (NBH) or without seed  resulted in no 250 
increase in ThT fluorescence over 72 h (Fig. 1A). However, because an inverse 251 
correlation existed between the rate of fibril formation and the concentration of rPrP (28, 252 
33), spontaneous formation of rPrP-fibrils (rPrP-fibspon) was induced by decreasing the 253 
concentration of rPrP from 100 to 50 μg/ml (Fig. 1A). 254 
We next examined the PK-resistance of rPrP-fibrils by immunoblotting using 255 
anti-PrP antibody R20 directed toward C-terminal residues 218–231. Although the 256 
ThT-negative reactions seeded with NBH or without seed produced no PK-resistant 257 
bands (Fig. 1B middle panel), the Chandler-seeded rPrP-fibrils (rPrP-fibCh) and 258 
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22L-seeded rPrP-fibrils (rPrP-fib22L) produced several (21-, 18-, 12-, 11-and 10-kDa) 259 
PK-resistant fragments (Fig. 1B, left panel). In contrast, the PK digestion of rPrP-fibspon 260 
generated only 10-12 kDa fragments. It should be noted that anti-PrP monoclonal 261 
antibody ICSM35 (directed toward an epitope consisting of residues 93-102) specifically 262 
recognized the 21- and 18 kDa fragments derived from PrPSc-seeded rPrP-fibrils in the 263 
first round (1st-rPrP-fibSc), indicating that they contained mouse PrP from about residues 264 
93-231 (Fig. 1B, right panel). 265 
To further characterize the structure of 1st-rPrP-fibSc and rPrP-fibspon, the 266 
samples were examined using a negative-stained transmission electron microscope 267 
(TEM). The electron micrographs of 1st-rPrP-fibCh and 1st-rPrP-fib22L revealed bundles of 268 
irregularly rod-shaped and branched fibrils, while most rPrP-fibspon displayed smooth and 269 
non-branched rod-shaped fibrils (Fig. 1C). Moreover, the lengths of 1st-rPrP-fibCh and 270 
1st-rPrP-fib22L were significantly longer than that of rPrP-fibspon (Fig. 1D). Thus, the 271 
results of TEM analysis suggest that 1st-rPrP-fibSc is structurally distinct from 272 
spontaneous rPrP-fibspon.   273 
We next examined the morphology of PrPSc-seeded rPrP-fibrils in the second 274 
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and fifth round reactions (2nd- and 5th-rPrP-fibSc) by TEM. In contrast to 1st-rPrP-fibSc, 275 
2nd- and 5th-rPrP-fibSc displayed spindly and non-branched fibrils or amorphous 276 
aggregates (Fig. 2). These data support the view that 1st-rPrP-fibSc are structurally distinct 277 
from those of 2nd- and 5th-rPrP fibSc. 278 
 279 
Structural characterization of rPrP-fibrils by FTIR 280 
We next examined the secondary structure of rPrP-fibrils and purified PrPSc from brains 281 
of mice infected with Chandler or 22L scrapie by FTIR. A silver-stained SDS-PAGE gel 282 
analysis revealed that Chandler- and 22L-PrPSc preparations were highly purified (Fig. 283 
3A). Furthermore, TEM analysis demonstrated that the PrPSc preparations consisted 284 
exclusively of amyloid-like fibrils (Fig. 3B). FTIR analysis showed that Chandler-PrPSc 285 
was characterized by a major band at 1630 cm-1 in the β-sheet region of second-derivative 286 
spectra, while 22L-PrPSc was characterized by two absorbance bands at 1631 and 1616 287 
cm-1 (Fig. 4A), indicating that there were conformational differences in β-sheet structures 288 
between Chandler- and 22L-PrPSc, as previously reported (7). Consistent with previous 289 
reports (6-9), bands of around 1656─1658 cm-1 were observed in both Chandler- and 290 
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22L-PrPSc. Although these bands were formerly attributed to α-helix, recent studies using 291 
direct mass spectrometric analysis of hydrogen/deuterium exchange and FTIR analysis 292 
have suggested that purified PrPSc has little α-helix content, and the bands probably result 293 
from turns (9, 34). Native rPrP had maximum absorbance at 1653 cm-1, which was 294 
congruent with that of prominent α-helical structures. In contrast, all rPrP-fibrils 295 
displayed prominent bands at lower wavenumbers (1630-1610 cm-1), indicating 296 
predominantly β-sheet content (Fig. 4A). The β-sheet spectra revealed conformational 297 
differences among rPrP-fibspon, 1st-rPrP-fibCh and 1st-rPrP-fib22L. The rPrP-fibspon had a 298 
prominent band at 1623 cm-1 and a modest band at 1610 cm-1. While the 1st-rPrP-fibCh 299 
was characterized by a single major band at 1624 cm-1, the 1st-rPrP-fib22L had two major 300 
maxima at 1629 and 1617 cm-1 (Fig. 4A). Although 1st-rPrP-fibSc lacked the bands around 301 
1656─1658 cm-1, the strain-specific shapes (one peak in Chandler versus two peaks in 302 
22L) in the β-sheet spectrum of the purified PrPSc resembled those of 1st-rPrP-fibSc.  303 
To test whether the strain-specific IR spectra observed in 1st-rPrP-fibCh and 304 
1st-rPrP-fib22L are transmitted to sequential QUIC reactions, we performed 5 serial rounds 305 
of QUIC (Supplementary Fig. 2). There was little difference in β-sheet spectra between 306 
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5th-rPrP-fibCh and 5th-rPrP-fib22L (Fig 3), suggesting that strain-specific conformations 307 
were lost in the 5th-rPrP-fibSc. Furthermore, additional experiments revealed that infrared 308 
spectra of rPrP-fibrils produced in the presence of low amount of PrPSc (1 pg) or under 309 
acidic conditions (pH 4) displayed little differences between strains (Fig. 4B). 310 
 311 
Conformational stability analysis of rPrP-fibrils and PrPSc  312 
To examine the biochemical differences of rPrP-fibrils and PrPSc in BH 313 
between strains, we performed a conformational stability assay, which combines GdnHCl 314 
denaturation with PK digestion. The [GdnHCl]1/2 values for Chandler- and 22L-PrPSc 315 
were 3.3 ± 0.4 and 1.7 ± 0.3 M, respectively (Fig. 5A and Table 1), indicating that the 316 
conformational stability of Chandler-PrPSc was significantly higher than that of 317 
22L-PrPSc. Consistent with previous work (11), Chandler-PrPSc bands treated with more 318 
than 1.5 M GdnHCl were approximately 5 kDa smaller than those treated with lower 319 
concentrations (Fig. 5A, upper panel). The [GdnHCl]1/2 of 1st-rPrP-fibCh and 320 
1st-rPrP-fib22L were 3.3 ± 0.1 and 2.3 ± 0.6 M, respectively (Fig. 5B and Table 1), 321 
showing that the stability of 1st-rPrP-fibCh was significantly higher than that of 322 
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1st-rPrP-fib22L, as with Chandler- and 22L-PrPSc. Thus, the relationship between Chandler 323 
and 22L in terms of conformational stability was common to both the original PrPSc and 324 
1st-rPrP-fibSc. In contrast, the [GdnHCl]1/2 of rPrP-fibspon was more than 5 M,  which was 325 
markedly higher than those of the 1st-rPrP-fibSc (Fig. 5B and Table 1). Additionally, we 326 
tested the conformational stability of 2nd- and 5th-rPrP-fibSc, but found no significant 327 
differences between strains (Fig. 5C, D and Table 1). 328 
 329 
Bioassay for rPrP-fibrils generated in QUIC reactions  330 
To determine whether the infectivity was transmitted to the rPrP-fibrils, we 331 
performed a bioassay using wild-type mice. To prepare the control materials, seed-only 332 
solutions containing the same concentration of PrPSc as 1st- or 5th-rPrP-fibSc were 333 
subjected to a mock RT-QUIC procedure and then mixed with the same amount of 334 
soluble rPrP (Table 2). The survival periods in mice inoculated with 40 µl aliquots 335 
containing rPrP-fibrils were 185.5 ± 4.0 days post-inoculation (dpi) for 1st-rPrP-fibCh and 336 
213.0 ± 8.9 dpi for 1st-rPrP-fib22L (Table 2). In contrast, the attack rate of these control 337 
mice was only 50% (2/4) for Chandler and 20% (1/5) for 22L. Moreover, the survival 338 
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periods of the affected mice were much longer than that of the mice inoculated with 339 
1st-rPrP-fibSc (Table 2). For comparison with the 50% lethal dose (LD50) of the original 340 
PrPSc, the LD50 of 1st-rPrP-fibSc was determined by the linear regression relationship 341 
between infectious titers and survival periods. The infectious titers (per 40 μl) of 342 
1st-rPrP-fibCh and 1st-rPrP-fib22L were estimated to be 407.2 ± 226.6 and 1067.0 ± 678.7 343 
LD50, respectively, whereas the titers of Chandler and 22L prion were 20.2 and 28.9 LD50 344 
units/40 pg of PrPSc, respectively. Because QUIC reaction in the first round resulted in a 345 
20- to 37-fold increase in the infectious titer, a seed contribution to the infectivity is 346 
estimated to be around 3−5%. In contrast, none of the mice inoculated with 5th-rPrP-fibSc 347 
developed symptoms related to TSE (Table 2), suggesting that the 5th-rPrP-fibSc has no 348 
substantial infectivity. 349 
We analyzed the levels of PrPSc in the brain tissues of terminal-stage mice 350 
inoculated with 1st-rPrP-fibSc or control materials (Mock 1st-QUIC) by Western blotting 351 
and found no apparent differences in the accumulation of PrPSc between them and the 352 
Mock 1st-QUIC (Fig. 6A). In addition, a conformational stability assay with GdnHCl 353 
revealed that the strain-specific digestion pattern was preserved in mice inoculated with 354 
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1st-rPrP-fibSc (Fig. 6B). 355 
Next, the degree of vacuolation in brain sections including the hippocampus 356 
(HI), cerebral cortex (Cx), thalamus (TH), pons (Po) and cerebellum (CE) from affected 357 
mice inoculated with 1st-rPrP-fibSc or Mock 1st-QUIC and those in the second passage of 358 
1st-rPrP-fibSc was examined histologically (Fig. 6C, D). Of note, we found that 359 
spongiform change of 1st-rPrP-fibSc-inoculated mice was less severe in HI and CE than 360 
that of Mock 1st-QUIC (Fig. 6C, D). Furthermore, these different lesion profiles observed 361 
in 1st-rPrP-fibSc-inoculated mice were preserved upon second passage (Fig. 6D), 362 
suggesting that 1st-rPrP-fibSc are partially distinct from the original strains. These 363 
findings support the notion that 1st-rPrP-fibSc provoke the emergence of a mutant strain 364 
beyond seed-derived infectivity.  365 
 366 
DISCUSSION 367 
Recent studies show that RT-QUIC assays are useful for the sensitive detection 368 
of PrPSc in most species and strains, including Creutzfeldt-Jakob disease (CJD) in humans 369 
(28, 35-37), scrapie in rodents (29, 38), and chronic wasting disease (CWD) in cervids 370 
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(39). In the RT-QUIC reaction, soluble rPrP is converted to amyloid fibrils in a 371 
seed-dependent fashion in the presence of PrPSc. Previous studies using FTIR and 372 
hydrogen/deuterium exchange have shown that there are structural differences between 373 
PrPSc-seeded and spontaneous rPrP-fibrils generated in the rPrP-PMCA (7, 40). We also 374 
found that the structural morphology (Fig. 1C), secondary structure (Fig. 3) and 375 
conformational stability (Fig. 4B and Table 1) distinguish 1st-rPrP-fibSc from rPrP-fibspon. 376 
However, it has been unknown whether rPrP retains the conformational properties of the 377 
original PrPSc in the RT-QUIC. Consistent with previous reports (7, 11), we observed 378 
strain differences in β-sheet structure and conformational stability of PrPSc between 379 
Chandler and 22L strains. Likewise, the differences in β-sheet spectrum shape between 380 
strains were common to both PrPSc and 1st-rPrP-fibSc. Furthermore, the conformational 381 
stability of 1st-rPrP-fib22L was significantly lower than that of 1st-rPrP-fibCh, as with 382 
Chandler- and 22L-PrPSc. Since the original PrP
Sc 
remaining in the 1st-rPrP-fibSc was 383 
equivalent to only about 0.01−0.02% of PK-resistant 1st-rPrP-fibSc (1−2 µg/10 µg of total 384 
PrP) in our estimation, the contribution to the FTIR spectra and the conformational 385 
stability of 1st-rPrP-fibSc is considered to be negligible. Taken together, these studies 386 
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demonstrate that at least some strain-specific conformational features, especially in the 387 
β-sheet region, are conserved between PrPSc and 1st-rPrP-fibSc. However, these unique 388 
structural features disappeared in subsequent rounds.  389 
One of the reasons for the loss of strain-specificity may be due to differences 390 
between E. coli-derived rPrP and brain-derived PrPC. Studies using circular dichroism  391 
and 1H-NMR spectroscopy showed that the tertiary structure and the thermal stability of 392 
bovine rPrP(23-230) are essentially identical to those of healthy calf brain-derived PrPC 393 
(41). However, it should be noted that E. coli-derived rPrP lacks posttranslational 394 
modifications of PrPC such as glycosylation and a glycosylphosphatidylinositol 395 
(GPI)-anchor. PrP has two N-linked glycosylation sites at amino acids 180 and 196, 396 
resulting in di-, mono- and unglycosylated forms. Mature PrPC is rich in the 397 
di-glycosylated form, whereas the glycoform ratio of PrPSc is known to vary among 398 
strains  (42-44). Studies using PrP glycan-lacking Tg mice revealed that the 399 
strain-specific characteristics of 79A strain were affected in by the glycosylation status of 400 
PrPC, but ME7 and 301C strains were not (45). Meanwhile, enzymatic deglycosylation of 401 
PrPC failed to affect strain-specific pathological changes in serial PMCA experiments 402 
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seeded with two murine strains, RML and 301C (46). However, the same two strains 403 
were converted into a new single strain during serial rPrP-PMCA in the presence of 404 
synthetic PE (27). Similarly, the emergence of mutant strains whose lesion profiles differ 405 
from that of the seed strain was also observed in the bioassay using hamster rPrP-fibrils 406 
generated in seeded rPrP-PMCA (25) or 1st-rPrP-fibSc (Fig. 6C, D). These results raise the 407 
possibility that the lack of a GPI-anchor in rPrP leads to alterations in the strain-specific 408 
characteristics. Furthermore, the cell tropisms determined by the Cell Panel Assay were 409 
altered in RML, 139A, 79A and ME7 strains but not in 22L when propagated in Tg mice 410 
expressing PrP devoid of a GPI-anchor (47). These studies demonstrate that 411 
glycosylation and a GPI-anchor are not necessarily required for the propagation of prion 412 
infectivity, but can influence the strain properties. Although the molecular basis of the 413 
emergence of mutant strains remains elusive, we can speculate that the posttranslational 414 
changes to PrP might affect the conformation of PrPSc or the interaction with some 415 
cofactor(s) in a strain-specific manner.  416 
Another possible explanation is that nonspecific rPrP-fibrils are generated 417 
during the serial RT-QUIC, and replicate more rapidly than the fibrils with strain-specific 418 
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conformation. The term “nonspecific rPrP-fibrils” arises from our findings that there was 419 
little difference in IR spectra and conformational stability of 5th-rPrP-fibSc between 420 
strains. It has been reported that the propagation of prion strains in cells cultured under 421 
different environments often leads to the formation of quasi-species that are assumed to 422 
be composed of a variety of conformational variants (48, 49). Once generated, the 423 
competition among the variants is thought to occur during propagation. Indeed, two 424 
conformational variants of rPrP-fibrils have been shown to be mutually exclusive and 425 
compete for monomeric rPrP as a substrate in the fibril formation (30). Furthermore, 426 
competitive amplification of two prion strains was demonstrated by BH-PMCA (50). 427 
Similarly, nonspecific rPrP-fibrils would be expected to become the majority if they had a 428 
selective growth advantage in the RT-QUIC. We found that the β-sheet spectra of 429 
rPrP-fibrils generated in the presence of low amount (1 pg) of PrPSc or rPrP-fibrils 430 
generated at pH 4 in the first round were similar to those seen in 5th-rPrP-fibSc  (Fig. 4B). 431 
These observations also support this hypothesis and suggest that the amplification of 432 
nonspecific rPrP-fibrils is accelerated by certain conditions such as an acidic environment. 433 
Further studies are needed to investigate whether unknown cofactors or environmental 434 
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conditions are required to maintain the strain-specific conformations in subsequent 435 
rounds. On the other hand, this hypothesis also explains why prion infectivity was lost in 436 
the fifth round of RT-QUIC, as nonspecific rPrP-fibrils generated during the serial 437 
RT-QUIC would be non-infectious. Although there remains the question as to what 438 
exactly are the conformational differences between the non-infectious and infectious 439 
forms of rPrP-fibrils, the lack of cofactor molecules such as SDS and synthetic PE in the 440 
RT-QUIC might enhance the amplification of nonspecific rPrP-fibrils lacking prion 441 
infectivity. Moreover, the facts that prion infectivity is sometimes too low to be detected 442 
and, more frequently, declines in the serial rPrP-PMCA (24, 25) or BH-PMCA (51-53) 443 
are consistent with the hypothesis.  444 
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FIGURE LEGENDS 623 
FIGURE 1.  The formation of rPrP-fibrils in RT-QUIC reactions. (A) The formation of 624 
rPrP-fibrils in the presence of diluted Chandler- or 22L-BH containing 100 pg of PrPSc, a 625 
comparable amount of NBH, or in the absence of seed (No-seeded) was monitored by 626 
ThT fluorescence. The graphs depict a representative of the RT-QUIC reactions. 627 
No-seeded reactions were performed at two different concentrations (100 or 50 µg/ml) of 628 
rPrP. (B) The QUIC reactions were digested with PK and immunoblotted using 629 
polyclonal anti-PrP antibody R20 (epitope located at mouse PrP amino acids 218-231) or 630 
ICSM35 (epitope 93-102). For comparison, 1st-rPrP-fibCh (50 ng of total rPrP) without 631 
PK digestion (PK (−)) is shown. Molecular mass markers are indicated in kilodaltons 632 
(kDa) on the left side of each panel. (C) Samples (1st-rPrP-fibCh, 1st-rPrP-fib22L and 633 
rPrP-fibspon) were examined with transmission electron microscopy (TEM). Scale bar, 634 
100 nm. (D) The bar graph shows the length and width of rPrP-fibspon, 1st-rPrP-fibCh and 635 
1st-rPrP-fib22L. The results are the mean ± SD of thirty rPrP-fibrils each. Statistical 636 
significance was determined using one-way analysis of variance (ANOVA) followed by 637 




FIGURE 2. The formation of PrPSc-seeded rPrP-fibrils in the second (2nd-rPrP-fibSc) and 640 
fifth rounds (5th-rPrP-fibSc) of RT-QUIC. (A) The former reactions were diluted 100-fold 641 
into fresh rPrP between each round. The reaction buffer contained 300 mM NaCl, 50 mM 642 
HEPES (pH7.5) and 10 µM ThT. The rPrP concentration was 100 µg/ml. (B) 643 
Transmission electron microscopic analysis of PrPSc-seeded rPrP-fibrils generated in the 644 
second, and fifth rounds of RT-QUIC. Scale bar, 100 nm. 645 
 646 
FIGURE 3. Silver staining and Western blot analysis of purified PrPSc. (A) The purified 647 
PrPSc samples (P) were examined by silver-stained SDS-PAGE gel analysis (left panel). 648 
For comparison, the electrophoretic pattern of prion-infected brain homogenates (BH) 649 
containing 100 µg total protein digested with PK (20 µg/ml, 37 oC for 1h) is shown (left 650 
panel). The purified PrPSc samples (P) were immunoblotted with polyclonal anti-PrP 651 
antibody M20 (right panel). Molecular mass markers (M) are indicated in kilodaltons 652 
(kDa) on the left side of each panel. (B) Electron microscopy analysis of purified 653 




FIGURE 4. FTIR spectroscopic characterization of rPrP-fibrils and purified PrPSc. (A) 656 
Second-derivative FTIR spectra are shown for purified PrPSc, 1st-rPrP-fibSc, 5th-rPrP-fibSc, 657 
spontaneous formation of rPrP-fibrils (rPrP-fibspon), and native rPrP. Overlaid spectra are 658 
from independent preparations. (B) FTIR spectra of rPrP-fibrils generated at pH 7.5 in the 659 
presence of low amount (1 pg) of PrPSc, and rPrP-fibrils generated at pH 4 in the presence 660 
of 100 pg of PrPSc.  661 
 662 
FIGURE 5.  Conformational stability assay for PrPSc in BH and rPrP-fibrils. (A) 663 
Chandler- (upper panel) or 22L (lower panel)-infected BH was treated with 0 to 3.5 M 664 
GdnHCl and subjected to PK digestion. PrPSc was detected by R20 anti-PrP polyclonal 665 
antibody. The denaturation curves were plotted using Boltzmann curve fit (right panel). 666 
(B–D) PK-digested 1st-rPrP-fibSc (generated as in Fig. 1) and rPrP-fibspon (B), 667 
2nd-rPrP-fibSc(C), or 5th-rPrP-fibSc (D) was analyzed by Western blotting following 668 
GdnHCl treatment (0 to 5M). The PK-resistant fragments of the rPrP-fibrils were 669 




FIGURE 6.  Bioassay of rPrP-fibrils in mice. (A) PrPSc in the brains of prion-affected 672 
mice inoculated with 1st-rPrP-fibCh or 1st-rPrP-fib22L was analyzed by Western blotting 673 
using anti-PrP antibody M20. M, Mock 1st-QUIC(Ch) or Mock 1st-QUIC(22L). (B) 674 
Strain-specific properties of PrPSc in the brains of 1st-rPrP-fibSc-inoculated mice were 675 
examined by a conformational stability assay with GdnHCl (0 to 3.5M). (C) Sections of 676 
the hippocampus (HI)) and cerebellum (CE), stained with hematoxylin and eosin, from 677 
normal mice, 1st-rPrP-fibSc-inoculated mice, and Mock 1st-QUIC-inoculated mice at 678 
terminal stages are shown. Scale bar, 50 µm. (D) Lesion profiles of spongiform changes 679 
in the hippocampus (HI), cerebral cortex (Cx), thalamus (TH), pons (Po) and cerebellum 680 
(CE) were compared. Data are expressed as means ± SD (n=3). Statistical significance 681 




TABLE 1. Conformational stabilities of purified PrPSc and rPrP-fibrilsa  684 
  rPrP-fibrils 
Strain Purified PrPSc 1st 2nd 5th 
Chandler 3.3 ± 0.4 ** 3.3 ± 0.1 * 3.7 ± 0.1 3.3 ± 0.3 
22L 1.7 ± 0.3 2.3 ± 0.6 3.8 ± 0.2 3.5 ± 1.0 
Spontaneous  > 5   
a The [GdnHCl]1/2 values (mol/l) are means ± SD of three independent experiments. 685 
Statistical significance was determined using one-way ANOVA followed by student’s 686 





TABLE 2. Bioassay for rPrP-fibrils generated in QUIC reactions in wild-type micea 690 
Inoculum Concentration of 





1st-rPrP-fibCh 1 185.5 ± 4.0* d 4/4 
Mock 1st-QUIC(Ch) c 1 201, 220 e 2/4 
1st-rPrP-fib22L 1 213.0 ± 8.9** d 6/6 
Mock 1st-QUIC(22L) c 1 333 e 1/5 
5th-rPrP-fibCh 1 × 10-8 > 660 f 0/4 
Mock 5th-QUIC(Ch) c 1 × 10-8 > 660 f 0/4 
5th-rPrP-fib22L 1 × 10-8 > 660 f 0/6 
Mock 5th-QUIC(22L) c 1 × 10-8 > 660 f 0/6 
rPrP-fibspon 0 > 660 f 0/6 
Second passage of 
1st-rPrP-fibCh 
 152.0 ± 8.5 d 5/5 
Second passage of 
Mock 1st-QUIC(Ch) g 
 148.4 ± 5.9 d 5/5 
Second passage of 
1st-rPrP-fib22L 
 153.5 ± 0.6 d 5/5 
Second passage of 
Mock 1st-QUIC(22L) h 
 149.6 ± 10.4 d 4/4 
a Mice were intracerebrally inoculated with 40 μl of each inoculum. For the second 691 
passage, 10% BH was used. Statistical significance was determined using Logrank test. 692 
**, p < 0.01; *, p < 0.05 (compared with the controls). 693 
b Days post-inoculation (dpi).  694 
c After subjecting seed-only mixtures containing the same concentration of PrPSc as 1st- or 695 
5th-rPrP-fibSc to a mock QUIC procedure, the same amount of rPrP was added. The 696 
solutions were inoculated into mice as controls for rPrP-fibrils. 697 
d Numbers represent means ± SD.  698 
e Numbers represent the survival periods of the TSE-positive mice. All non-symptomatic 699 
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mice were negative for PrPSc at 660 dpi. 700 
f Numbers represent dpi when the experiment was ended. 701 
g A 201-dpi mouse was used. 702 
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